Clinical Data

ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction

BioSpace

While survodutide's 16.6% overall weight loss was underwhelming, Boehringer Ingelheim and Zealand Pharma's drug achieved "impressive" fat loss, according to BMO Capital Markets.

Metabolic & GLP-1

Read full story

pharminent June 8, 2026 (Last updated: June 8, 2026)

BioSpace

While survodutide’s 16.6% overall weight loss was underwhelming, Boehringer Ingelheim and Zealand Pharma’s drug achieved “impressive” fat loss, according to BMO Capital Markets.

Metabolic & GLP-1

Read full story

Related Stories

Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data

ADC Therapeutics slumps on cancer drug safety scare

Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity

You May Have Missed

J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1B

ADA ’26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option

ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction

Incyte gobbles up Star’s Vega haematology unit in $2bn deal